{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335056","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-08-05T20:06:23+00:00","discovered_at":"2026-08-05T20:08:00.245896+00:00","generated_at":"2026-08-05T20:09:28.085659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sarepta Q2 net product revenue $328.7M; GAAP operating income $13.3M; narrows FY2026 guidance","bullets":["Net product revenue $328.7M: PMO $230.6M, ELEVIDYS $98.1M; total revenue $401.3M, down 34% YoY.","GAAP net loss $4.9M ($0.05 diluted loss); non-GAAP net income $78.6M ($0.64 diluted EPS).","Narrowed FY2026 net product revenue guidance to $1.2-$1.3B; non-GAAP R&D+SG&A to $800-$850M.","Appointed Michael Severino, MD, as CEO effective July 28, 2026; Doug Ingram retired.","Cash, equivalents, restricted cash and investments $945M, up ~$197M in the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335056","json":"https://secwatch.observer/filing/0001193125-26-335056.json","markdown":"https://secwatch.observer/filing/0001193125-26-335056.md","text":"https://secwatch.observer/filing/0001193125-26-335056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/0001193125-26-335056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:09:28.085659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}